Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503
10/10/2023 13:45
Oct 10 (Reuters) - ABL Bio Inc 298380.KQ :
* I-MAB AND ABL BIO ANNOUNCE LATEST UPDATES OF PD-L1 AND
4-1BB
BISPECIFIC ANTIBODY TJ-L14B/ABL503
* I-MAB - PATENT RIGHTS SECURED FOR TJ-L14B/ABL503 IN
EURASIA
UNTIL 2039
* I-MAB - AMONG 14 EFFICACY-EVALUABLE PATIENTS IN ONGOING
PHASE 1
STUDY, ONE ACHIEVED A COMPLETE RESPONSE
* I-MAB - AMONG 14 EFFICACY-EVALUABLE PATIENTS IN ONGOING
PHASE 1
STUDY, ONE HAD PARTIAL RESPONSE AND TWO UNCONFIRMED PARTIAL
RESPONSES
* I-MAB - MAXIMUM TOLERATED DOSE NOT YET REACHED
Source text for Eikon: ID:nPnbjClYTa
Further company coverage: 298380.KQ
((Reuters.Briefs@thomsonreuters.com))
Recent news on ABL Bio
See all newsBrief: Abl Bio Inc - Raises 37.7 Billion Won Worth Of New Shares
Brief: Abl Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases
Brief: Abl Bio Inc Signs Agreement With Intocell Inc To Use Its Antibody-Drug Conjugate Tech In Product Development
Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503
Brief: Abl Bio To Acquire Real Estate Worth 65 Billion Won